Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) rose 2.5% on Friday . The company traded as high as $3.27 and last traded at $3.24, with a volume of 291,182 shares traded. The stock had previously closed at $3.16.

RGLS has been the topic of a number of recent analyst reports. Chardan Capital reduced their price objective on shares of Regulus Therapeutics from $20.00 to $13.50 and set a “buy” rating on the stock in a research report on Tuesday, June 28th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, August 4th. Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 3rd. Cowen and Company reissued a “buy” rating on shares of Regulus Therapeutics in a research report on Wednesday, June 8th. Finally, Zacks Investment Research raised shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $10.17.

The company’s market cap is $171.14 million. The company has a 50-day moving average price of $3.51 and a 200 day moving average price of $5.46.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.02. On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post ($1.59) EPS for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.